Randomized, double-blind, placebo-controlled superiority trial of the Yiqigubiao pill for the treatment of patients with chronic obstructive pulmonary disease at a stable stage

In traditional Chinese medicine (TCM), the Yiqigubiao pill is commonly used to enhance physical fitness. The current clinical trial was designed to evaluate the efficacy and safety of the Yiqigubiao pill as an adjuvant therapy for patients with stable chronic obstructive pulmonary disease (COPD). Th...

Full description

Saved in:
Bibliographic Details
Published in:Experimental and therapeutic medicine 2016-10, Vol.12 (4), p.2477-2488
Main Authors: Li, Feng-Sen, Zhang, Yan-Li, Li, Zheng, Xu, Dan, Liao, Chun-Yan, Ma, Huan, Gong, Li, Su, Jun, Sun, Qi, Xu, Qian, Gao, Zhen, Wang, Ling, Jing, Jing, Wang, Jing, Jiang, Min, Tian, Ge, Hasan, Bilal
Format: Article
Language:English
Subjects:
Analysis
Blood gas analysis
Cancer therapies
Care and treatment
Chinese medicine
Chronic obstructive pulmonary disease
Clinical trials
Double-blind studies
Gallbladder diseases
Health aspects
Independent sample
Lung cancer
Lung diseases, Obstructive
Medicine, Chinese
randomized controlled trial
stable stage
Standard deviation
traditional Chinese medicine
Tuberculosis
Tumor necrosis factor-TNF
Yiqigubiao pill
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In traditional Chinese medicine (TCM), the Yiqigubiao pill is commonly used to enhance physical fitness. The current clinical trial was designed to evaluate the efficacy and safety of the Yiqigubiao pill as an adjuvant therapy for patients with stable chronic obstructive pulmonary disease (COPD). The current trial was a randomized, double-blind, placebo-controlled superiority trial. The participants were recruited from outpatients at the Traditional Chinese Medicine Hospital affiliated with Xinjiang Medical University (Ürümqi, China) between February and September 2012. All participants were patients with stable COPD that were randomized to the Yiqigubiao pill (YQGB; n=84) or placebo (Pb; n=87) groups. The occurrences of acute exacerbation (AE) of COPD during the trial were recorded. Lung function value assessments, scoring of life quality and exercise endurance, arterial blood gas analysis and serum inflammatory cytokines level determination were performed prior to and throughout the study. A total of 139 participants completed the intervention and 132 participants completed the study. The interval between the initial intervention and the first AECOPD was greater in the YQGB group compared with the Pb group (P
ISSN:1792-0981
1792-1015
DOI:10.3892/etm.2016.3680